Preclinical News and Research

RSS

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tiltan Pharma Ltd. today announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

14 Nov 2012

Tolvaptan improves kidney health in polycystic kidney disease

A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.

12 Nov 2012

Taste receptor governs respiratory infection susceptibility

The bitter taste receptor TAS2R38 may play a role in innate defense, say researchers, who have found that variations in the TAS2R38 gene may regulate susceptibility to respiratory infection.

12 Nov 2012

New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments are urgently needed for bacterial meningitis, a devastating disease which kills or maims around a fifth of people who contract it, according to medical experts writing in a new Series on bacterial meningitis, published in The Lancet.

9 Nov 2012

Inactivating beta2 subunit of nicotinic receptors may help smokers quit without feeling anxious

Preclinical data suggests inactivation of a specific sub-class of nicotinic receptors may be an effective strategy to help smokers quit without feeling anxious, according to Virginia Commonwealth University researchers.

9 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

HCT 1026 may help stem debilitating effects of muscular dystrophy

Cedars-Sinai Heart Institute researchers have found that an experimental compound may help stem the debilitating effects of muscular dystrophy by restoring normal blood flow to muscles affected by the genetic disorder.

9 Nov 2012

UIC researchers develop transgenic Alzheimer's mouse with apoE4 gene

Researchers at the University of Illinois at Chicago College of Medicine have developed a transgenic mouse that carries a human gene known to increase risk of Alzheimer's 15-fold. This new mouse mimics the genetics of the human disease more closely than any of the dozen existing mouse models and may prove more useful in the development of candidate drugs to prevent or treat the disease.

9 Nov 2012

Autism onset age predicts pattern of development in early years

Researchers have found that the pattern of development differs over the first 3 years of life between children with early- and later-onset autism spectrum disorder.

8 Nov 2012

Pevion launches Defensomes platform for broad spectrum immune enhancement

Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial.

8 Nov 2012

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC).

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

EUROECHO 2012 reveals how imaging improves early diagnosis of atherosclerosis

"Atherosclerosis is the leading cause of cardiovascular disease and the leading killer in Europe," said Professor Patrizio Lancellotti, President-Elect of the EACVI and Chairman of the EUROECHO Scientific Programme Committee. "Many of these deaths could be averted by diagnosis at a preclinical stage or early after the onset of symptoms."

8 Nov 2012

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Overweight, smoking add to rheumatoid arthritis risk

Lifestyle changes could reduce the risk for rheumatoid arthritis in patients predisposed to the condition, Dutch researchers suggest.

5 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

3 Nov 2012

Preclinical News and Research

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tolvaptan improves kidney health in polycystic kidney disease

Taste receptor governs respiratory infection susceptibility

New vaccines and drug treatments urgently needed for bacterial meningitis

Inactivating beta2 subunit of nicotinic receptors may help smokers quit without feeling anxious

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

HCT 1026 may help stem debilitating effects of muscular dystrophy

UIC researchers develop transgenic Alzheimer's mouse with apoE4 gene

Autism onset age predicts pattern of development in early years

Pevion launches Defensomes platform for broad spectrum immune enhancement

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

EUROECHO 2012 reveals how imaging improves early diagnosis of atherosclerosis

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Overweight, smoking add to rheumatoid arthritis risk

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics